Skip Navigation

European Heart Journal 1999 20(16):1182-1190; doi:10.1053/euhj.1998.1481
Copyright © 1999 by the European Society of Cardiology.
This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (65)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bart, B.A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bart, B.A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry

B.A. Barta,f1, G. Ertlb, P. Heldc, J. Kuchd, A.P. Maggionie, J. McMurrayf, E.L. Michelsong, J.L. Rouleauh, L. Warner Stevensoni, K. Swedbergj, J.B. Youngk, S. Yusufl, M.A. Sellersa, C.B. Grangera, R.M. Califfa and M.A. Pfeffer for the SPICE investigatorsi

a Duke University, Durham, U.S.A.
b II.Med. Universitätsklinik Mannheim/Heidelberg, Heidelberg, Germany
c Astra Hassle, Goteborg, Sweden
d Warsaw University School of Medicine, Warsaw, Poland
e GISSI group, Milano, Italy
f University of Glasgow, Glasgow, U.K.
g Astra Pharmaceuticals LP, Wayne, U.S.A.
h Montreal Heart Institute, Montreal, Canada
i Brigham & Women's Hospital, Boston, U.S.A.
j Goteborg University, Goteborg, Sweden
k Cleveland Clinic, Cleveland, U.S.A.
l McMaster University, Hamilton, Canada

revised December 15, 1998; accepted December 16, 1999 1999

Abstract

Aims The reported prevalence of angiotensin-converting enzyme (ACE) inhibitor use in patients with heart failure varies considerably. Recent reports suggest that many patients who could benefit from such therapy are not receiving ACE inhibitors. The Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry was established to understand better the demographics, characteristics, and contemporary use of ACE inhibitors in an international registry.

Methods and Results Between August 1996 and April 1997, each of 105 study centres from eight countries in North America and Europe was invited to review retrospectively the medical records of 100 consecutive patients with left ventricular ejection fractions ≤35%. The median age of the 9580 Registry patients was 66 years, 26% were women, the median ejection fraction was 27%, and the primary aetiology of left ventricular dysfunction was ischaemic (63%). Eighty percent of patients were receiving ACE inhibitors. The most common reason for non-use of ACE inhibitors was intolerance (9%).

Conclusion The SPICE Registry provides a contemporary description of the demographics and management of patients with documented left ventricular systolic dysfunction. The contemporary use of ACE inhibitors (80%) appears to be higher than previously reported and the main reason for non-use is perceived intolerance (9%).

Key Words: Heart failure, ACE inhibitor, management, medication usage

f1 Correspondence: Bradley A. Bart, MD, Assistant Professor of Medicine, Division of Cardiology, Hennepin County Medical Center, 865A, 701 Park Avenue South, Minneapolis, Minnesota 55415, U.S.A.

References

  1. Anonymous. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med. 1987;316:1429–1435[Abstract]
  2. Anonymous, Heart failure: management of patients with left-ventricular systolic dysfunction. Agency for Health Care Policy and Research. Clinical Practice Guideline—Quick Reference Guide for Clinicians, 1994, 1, 25
  3. Garg, R, Yusuf, S, Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials [published erratum appears inJAMA, 1995, 274, 462, JAMA, 1995, 273, 1450, 6
  4. Cohn JN. The management of chronic heart failure. N Engl J Med. 1996;335:490–498[Free Full Text]
  5. Clarke KW, Gray D, Hamptom JR. Evidence of inadequate investigation and treatment of patients with heart failure. Br Heart J. 1994;71:584–587[Abstract/Free Full Text]
  6. Stevenson WG, Stevenson LW, Middlekauff HR. Improving survival for patients with advanced heart failure: a study of 737 consecutive patients. J Am Coll Cardiol. 1995;26:1417–1423[Abstract]
  7. Bart BA, Gattis WA, Diem SJ, O'Connor CM. Reasons for underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction. Am J Cardiol. 1997;79:1118–1120[CrossRef][Web of Science][Medline]
  8. Rich MW, Beckham V, Wittenberg C, Leven CL, Freedland KE, Carney RM. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med. 1995;333:1190–1195[Abstract/Free Full Text]
  9. Philbin EF, Andreaou C, Rocco TA, Lynch LJ, Baker SL. Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals. Am J Cardiol. 1996;77:832–838[CrossRef][Web of Science][Medline]
  10. Anonymous. Mortality risk and patterns of practice in 4606 acute care patients with congestive heart failure. The relative importance of age, sex, and medical therapy. Clinical Quality Improvement Network Investigators. Arch Intern Med. 1996;156:1669–1673[Abstract/Free Full Text]
  11. Anonymous. Heart failure treatment with angiotensin-converting enzyme inhibitors in hospitalized Medicare patients in 10 large states. The Large State Peer Review Organization Consortium. Arch Intern Med. 1997;157:1103–1108[Abstract/Free Full Text]
  12. Stafford RS, Saglam D, Blumenthal D. National patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure. Arch Intern Med. 1997;157:2460–2464[Abstract/Free Full Text]
  13. Anonymous. Survey on heart failure in Italian hospital cardiology units: Results from the SEOSI study. Eur Heart J. 1997;18:1457–1464[Abstract/Free Full Text]
  14. Schocken DD, Arrieta MI, Leaverton PE, Ross EA. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol. 1992;20:301–306[Abstract]
  15. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 1993;88:107–115[Abstract/Free Full Text]
  16. Rodeheffer RJ, Jacobsen SJ, Gersh BJ. The incidence and prevalence of congestive heart failure in Rochester, Minnesota. Mayo Clinic Proceedings. 1993;68:1143–1150[Web of Science][Medline]
  17. Krumholz HM, Parent EM, Tu N. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med. 1997;157:99–104[Abstract/Free Full Text]
  18. Reis SE, Holubkov R, Edmundowicz D. Treatment of patients admitted to the hospital with congestive heart failure: specialty-related disparities in practice patterns and outcomes. J Am Coll Cardiol. 1997;30:733–738[Abstract]
  19. Oka RK, Fortmann SP, Varady AN. Differences in treatment of acute myocardial infarction by sex, age, and other factors (the Stanford Five-City Project). Am J Cardiol. 1996;78:861–865[CrossRef][Web of Science][Medline]
  20. Steingart RM, Packer M, Hamm P. Sex differences in the management of coronary artery disease. Survival and Ventricular Enlargement Investigators. N Engl J Med. 1991;325:226–230[Abstract]
  21. Ayanian JZ, Epstein AM. Differences in the use of procedures between women and men hospitalized for coronary heart disease. N Engl J Med. 1991;325:221–225[Abstract]
  22. Pilote L, Califf RM, Sapp S. Regional variation across the United States in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. N Engl J Med. 1995;333:565–572[Abstract/Free Full Text]
  23. Eisenberg MJ, Califf RM, Cohen EA, Adelman AG, Mark DB, Topol EJ. Use of evidence-based medical therapy in patients undergoing percutaneous coronary revascularization in the United States, Europe, and Canada. Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I) and Canadian Coronary Atherectomy Trial (CCAT) investigators. Am J Cardiol. 1997;79:867–872[CrossRef][Web of Science][Medline]
  24. Hillis GS, Al-Mohammad A, Wood M, Jennings KP. Changing patterns of investigation and treatment of cardiac failure in hospital. Heart. 1996;76:427–429[Abstract/Free Full Text]
  25. Pfeffer MA, Braunwald E, Moye LA. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669–677[Abstract]
  26. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med. 1992;117:234–242[Abstract/Free Full Text]
  27. Kostis JB, Shelton BJ, Yusuf S. Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the Studies of Left Ventricular Dysfunction. Am Heart J. 1994;128:358–364[CrossRef][Web of Science][Medline]
  28. Kostis JB, Shelton B, Gosselin G. Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators. Am Heart J. 1996;131:350–355[CrossRef][Web of Science][Medline]
  29. Packer M, O'Connor CM, Ghali JK. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med. 1996;335:1107–1114[Abstract/Free Full Text]
  30. Packer M, Bristow MR, Cohn JN. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349–1355[Abstract/Free Full Text]
  31. Anonymous. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991;325:293–302[Abstract]
  32. Anonymous. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med. 1997;336:525–533[Abstract/Free Full Text]
  33. Loeb HS, Johnson G, Henrick A. Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation. 1993;87:VI78–87
  34. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet. 1994;344:493–498[CrossRef][Web of Science][Medline]
  35. Wei JY. Age and the cardiovascular system. N Engl J Med. 1992;327:1735–1739[Web of Science][Medline]
  36. Luchi RJ, Snow E, Luchi JM, Nelson CL, Pircher FJ. Left ventricular function in hospitalized geriatric patients. J Am Ger Soc. 1982;30:700–705[Web of Science][Medline]
  37. Bart BA, Shaw LK, McCants CBJ, Fortin DF, Lee KL, Califf RM. Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. J Am Coll Cardiol. 1997;30:1002–1008[Abstract]
  38. Lindenfeld J, Krause-Steinrauf H, Salerno J. Where are all the women with heart failure. J Am Coll Cardiol. 1997;30:1417–1419[Abstract]
  39. Bourassa M, Gurne O, Bangdiwala S. Natural history and patterns of current practice in heart failure. The Studies of Left Ventricular Dysfunction (SOLVD) Investigators. J Am Coll Cardiol. 1993;22:14A–29A[Medline]
  40. Bangdiwala SI, Weiner DH, Bourassa MG, Friesinger GCd, Ghali JK, Yusuf S. Studies of Left Ventricular Dysfunction (SOLVD) Registry: rationale, design, methods and description of baseline characteristics. Am J Cardiol. 1992;70:347–353[CrossRef][Web of Science][Medline]
  41. Young JB, Weiner DH, Yusuf S. Patterns of medication use in patients with heart failure: a report from the Registry of Studies of Left Ventricular Dysfunction (SOLVD). South Med J. 1995;88:514–523[Web of Science][Medline]
  42. Pfeffer MA, Stevenson LW. Beta-adrenergic blockers and survival in heart failure [editorial; comment]. N Engl J Med. 1996;334:1396–1397[Free Full Text]
  43. Doughty RN, Rodgers A, Sharpe N, MacMahon S. Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials. Eur Heart J. 1997;18:560–565[Abstract/Free Full Text]
  44. Epstein AE, Hallstrom AP, Rogers WJ. Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST). JAMA. 1993;270:2451–2455[Abstract/Free Full Text]
  45. Anonymous. The effect of diltiazem on mortality and reinfarction after myocardial infarction. The Multicenter Diltiazem Postinfarction Trial Research Group. N Engl J Med. 1988;319:385–392[Abstract]
  46. Furberg, CD, Psaty, BM, Meyer, JV, Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation, 1995, 92, 1326, 31
  47. Lamas GA, Pfeffer MA, Hamm P, Wertheimer J, Rouleau JL, Braunwald E. Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? The SAVE Investigators. N Engl J Med. 1992;327:241–247[Abstract]
  48. Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: Rationale for preventive strategies and comprehensive disease management. Am Heart J. 1997;133:703–712[CrossRef][Web of Science][Medline]
  49. Anonymous. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). J Am Coll Cardiol. 1995;26:1376–1398[Web of Science][Medline]
  50. Anonymous. The treatment of heart failure. Task Force of the Working Group on Heart Failure of the European Society of Cardiology. Eur Heart J. 1997;18:736–753[Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Stat Methods Med ResHome page
R. F Potthoff, G. E Tudor, K. S Pieper, and V. Hasselblad
Can one assess whether missing data are missing at random in medical studies?
Statistical Methods in Medical Research, June 1, 2006; 15(3): 213 - 234.
[Abstract] [PDF]

Home page
 Eur J Heart FailHome page
B. Westendorp, R. G. Schoemaker, H. Buikema, F. Boomsma, D. J. van Veldhuisen, and W. H. van Gilst
Progressive left ventricular hypertrophy after withdrawal of long-term ACE inhibition following experimental myocardial infarction
Eur J Heart Fail, March 1, 2006; 8(2): 122 - 130.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
J. J.V. McMurray
The role of angiotensin II receptor blockers in the management of heart failure
Eur. Heart J. Suppl., October 1, 2005; 7(suppl_J): J10 - J14.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
G. Ertl and S. Frantz
Wound model of myocardial infarction
Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H981 - H983.
[Full Text] [PDF]

Home page
 CirculationHome page
J. B. Young, M. E. Dunlap, M. A. Pfeffer, J. L. Probstfield, A. Cohen-Solal, R. Dietz, C. B. Granger, J. Hradec, J. Kuch, R. S. McKelvie, et al.
Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction: Results of the CHARM Low-Left Ventricular Ejection Fraction Trials
Circulation, October 26, 2004; 110(17): 2618 - 2626.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
M. Kittleson, S. Hurwitz, M. R. Shah, A. Nohria, E. Lewis, M. Givertz, J. Fang, J. Jarcho, G. Mudge, and L. W. Stevenson
Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality
J. Am. Coll. Cardiol., June 4, 2003; 41(11): 2029 - 2035.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
M.A. Weber
Angiotensin receptor blockers and the cardiovascular continuum: what future is indicated by recent successes?
Eur. Heart J. Suppl., April 1, 2003; 5(suppl_C): C1 - C4.
[Abstract] [PDF]

Home page
 Eur Heart J SupplHome page
J.N. Cohn
Val-HeFT: changing the heart failure horizon
Eur. Heart J. Suppl., April 1, 2003; 5(suppl_C): C25 - C28.
[Abstract] [PDF]

Home page
 HeartHome page
A P Maggioni, G Sinagra, C Opasich, E Geraci, M Gorini, E Gronda, D Lucci, G Tognoni, E Balli, and L Tavazzi
Treatment of chronic heart failure with {beta} adrenergic blockade beyond controlled clinical trials: the BRING-UP experience
Heart, March 1, 2003; 89(3): 299 - 305.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
A. P. Maggioni, I. Anand, S. O. Gottlieb, R. Latini, G. Tognoni, J. N. Cohn, and the Val-HeFT Investigators
Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors
J. Am. Coll. Cardiol., October 16, 2002; 40(8): 1414 - 1421.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
B. H. Greenberg
Angiotensin receptor blockers in heart failure: A work in progress
J. Am. Coll. Cardiol., October 16, 2002; 40(8): 1422 - 1424.
[Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
J. M. Fink
The Use of Angiotensin-II Receptor Blockers in Heart Failure
Journal of Pharmacy Practice, August 1, 2002; 15(4): 318 - 325.
[Abstract] [PDF]

Home page
 J Am Coll CardiolHome page
P. Jong, C. Demers, R. S. McKelvie, and P. P. Liu
Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials
J. Am. Coll. Cardiol., February 6, 2002; 39(3): 463 - 470.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Renin-Angiotensin-Aldosterone SystemHome page
H. Skali and M. A Pfeffer
Review: Prospects for ARB in the next five years
Journal of Renin-Angiotensin-Aldosterone System, December 1, 2001; 2(4): 215 - 218.
[PDF]

Home page
 Arch Intern MedHome page
D. J. Whellan, L. Gaulden, W. A. Gattis, B. Granger, S. D. Russell, M. A. Blazing, M. S. Cuffe, and C. M. O'Connor
The Benefit of Implementing a Heart Failure Disease Management Program
Arch Intern Med, October 8, 2001; 161(18): 2223 - 2228.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
P. Bellotti, L.P. Badano, N. Acquarone, R. Griffo, G. Lo Pinto, A.P. Maggioni, C. Mattiauda, G. Menardo, and P. Mombelloni
Specialty-related differences in the epidemiology, clinical profile, management and outcome of patients hospitalized for heart failure. The OSCUR study
Eur. Heart J., April 1, 2001; 22(7): 596 - 604.
[Abstract] [PDF]

Home page
 Arch Intern MedHome page
A. H. Jamali, W. H. W. Tang, U. N. Khot, and M. B. Fowler
The Role of Angiotensin Receptor Blockers in the Management of Chronic Heart Failure
Arch Intern Med, March 12, 2001; 161(5): 667 - 672.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
S. Stewart, L. Blue, S. Capewell, J. D. Horowitz, and J. J. McMurray
Poles apart, but are they the same? A comparative study of Australian and Scottish patients with chronic heart failure
Eur J Heart Fail, March 1, 2001; 3(2): 249 - 255.
[Abstract] [Full Text] [PDF]

Home page
 SEMIN CARDIOTHORAC VASC ANESTHHome page
L. L. Clark
Perioperative Treatment of Congestive Heart Failure
Seminars in Cardiothoracic and Vascular Anesthesia, November 1, 2000; 4(4): 223 - 235.
[Abstract] [PDF]

Home page
 HeartHome page
J. J McMurray and S. Stewart
HEART FAILURE: Epidemiology, aetiology, and prognosis of heart failure
Heart, May 1, 2000; 83(5): 596 - 602.
[Full Text]

Home page
 JAMAHome page
R. M. Califf and C. M. O'Connor
{beta}-Blocker Therapy for Heart Failure: The Evidence Is In, Now the Work Begins
JAMA, March 8, 2000; 283(10): 1335 - 1337.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
K. Dickstein
ACE inhibitor use in heart failure: would that it were so
Eur. Heart J., August 2, 1999; 20(16): 1145 - 1146.
[PDF]

Home page
 Physiol. GenomicsHome page
S. C. FRANCIS, M. K. RAIZADA, A. A. MANGI, L. G. MELO, V. J. DZAU, P. R. VALE, J. M. ISNER, D. W. LOSORDO, J. CHAO, M. J. KATOVICH, et al.
Genetic targeting for cardiovascular therapeutics: are we near the summit or just beginning the climb?
Physiol Genomics, December 21, 2001; 7(2): 79 - 94.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (65)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bart, B.A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bart, B.A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?